The SITC 2017 Microlearning: Acquired Resistance Series has been developed with content from abstract and faculty presentations conducted at theSociety for Immunotherapy of Cancer 32nd Annual Meeting (SITC 2017). The microlearning series provide a quick, easily accessible format for clinicians and researchers to learn about the latest advances in cancer immunotherapy from experts in the field.
The Acquired Resistance Series contains three modules.
Module 1: Acquired Resistance Checkpoint Inhibitors in Lung Cancer
Katerina Politi, PhD - Yale School of Medicine
Module 2: Acquired Resistance to PD-1 Blockade in Melanoma
Antoni Ribas, MD, PhD - University of California, Los Angeles
Module 3: Acquired Resistance in Melanoma
Annette Paschen, MD - University Hospital Essen
These modules have been designed to meet the educational needs of researchers and healthcare professionals involved in cancer research and clinical care.
Course Available Beginning: August 16, 2018
Course Objectives Upon completion of this activity, participants will be able to:
Describe commonly targeted mechanisms that can result in acquired resistance to immunotherapy.
Provide specific examples of acquired resistance to immunotherapy.
Characterize differences in acquired resistance between diseases.
The SITC connectED education portal is supported by independent educational grants from AstraZeneca Pharmaceuticals LP and Merck & Co., Inc.
Cookies are small pieces of information that are stored by your browser on your computerâ€™s hard drive.
You can delete or block cookies within your browser settings.
Should you opt to do this, some parts of our site may not work.
For more information, including instructions on how to remove the cookies that have been placed,